Fibrinolysis of acute peripheral arterial occlusion with tenecteplase--a new weight-optimized treatment regimen.
Peripheral arterial occlusions are associated with high morbidity. Thrombolysis has become established as effective treatment in clinical practice. Tenecteplase is a new thrombolytic agent that offers advantages over existing drugs with respect to mechanism of action and adverse effects. This case report describes successful thrombolysis of an acute thromboembolic brachial artery subtotal occlusion in a 76-year-old woman. In contrast to previously published data, tenecteplase was administered in a weight-adapted dose regimen over six hours, with application of one-fourth of the dose usually given in patients with myocardial infarction. Tenecteplase was immediately effective, and proved safe and well tolerated.
Melzer
Christoph
C
Medical Clinic, Charité University Medical Center, Schumannstrasse 20/21, D-10117 Berlin, Germany. christoph.melzer@charite.de
Richter
Christoph
C
Kröncke
Thomas
T
Theres
Heinz
H
Baumann
Gert
G
Laule
Michael
M
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011859:Radiography; D000077785:Tenecteplase; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase